The questions seem simple enough: Is there a best site on your body to inject a GLP-1 medication? Will one site provide better absorption, fewer side effects, or greater success than another?

The short answer is no. But when the question is asked on social media, it prompts a torrent of responses and strong opinions, frequently from people with no medical background.

Michelle E. Gordon, DO, an obesity medicine direct-pay physician in Westchester, New York, who frequently posts on social media, recently received that question from a viewer. She explained that what matters is injecting the medication beneath the skin at one of the three approved sites: the abdomen, thigh, or upper arm.

To date, that post has garnered more than a thousand reactions and 137 comments on Facebook. After hearing Gordon’s answer, users offered widely varying opinions that didn’t always align with her conclusions.

One person claimed that injecting into the right side of abdomen caused less nausea than injecting into the left. Another said that only abdominal injections worked. One user reported that their weight loss had stalled with abdominal injections but resumed after switching to the thigh.

Elizabeth Massey, PA-C, an Atlanta physician assistant with 17,000 Facebook followers who often posts about GLP-1s, also frequently gets asked about the “best” injection site.

“I tell them there is not a best place,” she told Medscape Medical News.

Massey explains that the absorption rate is similar at each of the recommended sites but acknowledges that people often develop individual preferences. She advises patients to rotate injection sites each week to reduce scar tissue formation.

And when GLP-1 users ask whether they can choose an injection site based on where they want to lose the most weight, she has to tell them that, unfortunately, it doesn’t work that way.

FDA and Manufacturers Recommend Abdomen, Thigh, or Upper Arm

The FDA-approved prescribing information for injectable GLP-1 medications recommends three injection sites: the abdomen, thigh, and upper arm. For upper-arm injections, manufacturers suggest having someone else administer the injection because the area can be difficult to reach.

GLP-1 users are also encouraged to talk to their clinician about the injection site best suited to them, said a spokesperson for Novo Nordisk, which manufactures Wegovy and Ozempic.

Doctors Weigh In

Questions about the best injection site are not confined to social media. Gordon said the issue also comes up among colleagues at obesity medicine meetings and in a WhatsApp discussion group.

Gordon advises her fellow clinicians to tell patients: “It doesn’t matter [which of the approved sites is selected] as long as it goes beneath your skin.”

She reminds patients that GLP-1 medications should be administered subcutaneously, not intramuscularly.

The goal is to inject where there is subcutaneous fat, agreed Michael Weintraub, MD, an endocrinologist and obesity specialist and clinical assistant professor of medicine at NYU Langone, New York City.

He reassures patients concerned about finding the “best” injection site that, as long as the medication is injected into one of the recommended areas of subcutaneous fat, “it doesn’t end up mattering on effectiveness.”

Gordon, Weintraub, and Massey said they were unaware of studies comparing the effectiveness of different injection sites for GLP-1s and doubted that such a study would be conducted.

Personal Preferences Rule

Even without evidence that one site is superior, GLP-1 users maintain strong personal preferences. Medscape Medical News asked several users to share their experiences.

Nancy Tarbox, 66, of Bradley, South Dakota, has been taking Zepbound since July 2025.

“I’ve not used my leg,” she said. “Every Thursday, I inject usually one side or the other of my lower stomach.”

She has followed that routine as she progressed from the starting dose to her current one. Because it is working for her, she sees no need to switch.

Shelly Groves, 63, an Atlanta pet sitter, has been taking a GLP-1 since May 2023 and has lost 62 pounds. She has rotated her injection sites and said she noticed differences in side effects depending on where she injects.

“When I started, I started with the stomach,” she said. She experienced some queasiness — “not terrible side effects,” she said, but noticeable.

When Groves injects into her thigh, she notices fewer side effects. Recently, she has begun injecting into the back of her upper arm and alternating arms. The previous week, she returned to an abdominal injection to see whether it might suppress her appetite more, despite the possibility of increased queasiness.

Gordon has lost 35 pounds since beginning a GLP-1 in December 2024 and injects into her abdomen. She administers the injection slowly to make it more comfortable, describing herself as “a former surgeon who is afraid of needles.”

Massey has been taking a GLP-1 for 2 years. She said abdominal injections cause her nausea, whereas upper-arm injections do not, making it her preferred site.

What Clinicians Can Tell Patients

Clinicians can expect to spend time dispelling misinformation patients encounter on social media. One recent post from a person with no stated medical background, for example, claimed that not all injection sites “hit the same.”

At the same time, clinicians can acknowledge patients’ individual experiences and preferences while explaining that there is no established evidence that one approved injection site is more effective or better tolerated than another.

“People have a lot of opinions about this,” Gordon said. But those opinions are based on personal experience, she noted, an important distinction to keep in mind.

Weintraub has no disclosures. Massey also works as an independent contractor affiliate with Belle Health, a telemedicine company, and sometimes earns commission independent of her social media posts and videos. Gordon reported owning shares in Eli Lilly and Viking Therapeutics.